AbCellera Biologics (ABCL) Corporate presentation summary

Company overview and financial position

• Clinical-stage biotech focused on novel antibody medicines, founded in 2012, with ~600 employees and facilities in Vancouver, Montreal, and Sydney.

• Maintains strong liquidity with $565M+ in cash and securities, plus $110M in available government funding as of June 30, 2026.

• Over $1B invested in its integrated antibody drug platform, supporting both internal and partner-led programs.

• More than 100 partner-led programs supported, with 12 molecules from these programs progressing in the clinic.

Strategic focus and pipeline

• Shifted focus in 2023 from partnerships to advancing an internal pipeline of differentiated antibody assets.

• Pipeline includes 2 molecules in the clinic, 2 in IND-enabling activities, and 20+ discovery programs.

• Key targets include GPCR and ion channel targets, with novel modalities such as multispecifics and ADCs.

• Indication-agnostic approach, with programs spanning endocrinology, immunology, autoimmunity, and oncology.

2026 priorities and clinical milestones

• ABCL635 Phase 2 top-line data readout completed in August 2026, supporting advancement to late-stage development.

• ABCL575 Phase 1 top-line data expected in Q4 2026; ABCL688 and ABCL386 progressing through IND-enabling activities.

• Plans to nominate at least one additional development candidate for IND-enabling activities in 2026.

• Multiple catalysts anticipated in 2027, including late-stage development and potential out-licensing.